Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681030 · ClinicalTrials.gov registry record · Phase 2
The Fibrin Pad Cardiovascular Study
A Phase 2 study of Cardiovascular Disease, sponsored by Ethicon.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT01681030 is a Phase 2 study of Cardiovascular Disease that has completed, run by Ethicon. The registered enrollment target is 42 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT01681030, a Phase 2 study of Cardiovascular Disease, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a three-arm, randomized multicenter study evaluating the safety and effectiveness of EVARREST™ Fibrin Sealant Patch in controlling mild to moderate vascular anastomosis suture line bleeding in cardiovascular surgery.
Conditions Studied
Interventions
- OTHER Standard of Care
- BIOLOGICAL EVARREST™
- BIOLOGICAL Topical hemostat
Study Locations (6)
New Jersey
- Clinical Investigation Site #4 - Camden
- Clinical Investigation Site #1 - Paterson
New York
- Clinical Investigation Site #3 - New York
- Clinical Investigation Site #2 - New York
Indiana
- Clinical Investigation Site #5 - Indianapolis
Missouri
- Clinical Investigation Site #6 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2013-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681030
The ClinicalTrials.gov registry entry for NCT01681030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT01681030 reports 6 study locations spanning 4 distinct geographic areas - top geographies include New Jersey, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT01681030 about?
NCT01681030 is a clinical study titled "The Fibrin Pad Cardiovascular Study". This is a three-arm, randomized multicenter study evaluating the safety and effectiveness of EVARREST™ Fibrin Sealant Patch in controlling mild to moderate vascular anastomosis suture line bleeding in cardiovascular surgery.
What is the current status of trial NCT01681030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-08-01. Estimated completion is 2013-09-03.
What conditions does trial NCT01681030 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT01681030?
The interventions under investigation include: Standard of Care (OTHER), EVARREST™ (BIOLOGICAL), Topical hemostat (BIOLOGICAL).
Who is sponsoring clinical trial NCT01681030?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01681030 being conducted?
This trial has 6 study locations across Indiana, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Reduction of Smoking in Cardiac Disease Patients
COMPLETED · Phase 2
-
Trial of Oral Glutamine on Mitochondrial Function in CKD
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.